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Indefinite donor-specific tolerance to a cardiac allograft can be induced 
through pretransplantation i trathymic injection of donor spleen cells and 
a single intraperitoneal injection of antilymphocyte serum. This study was 
designed to determine whether this phenomenon was reproducible with 
grafts differing in either class I major histocompatibility complex only or 
class II MHC only. Donors of cells and hearts in all experiments were RP 
rats. Class I MHC disparate grafts were performed by placing an RP heart 
into a Lewis recipient, and class II disparate grafts were performed with RP 
donors and Wistar Furth recipients. Lewis (n = 10) and Wistar Furth (n = 
10) recipients underwent intraperitoneal injection of 1 ml antilympocyte 
serum and intrathymic injection of 5 × 10 7 RP spleen cells. Three weeks 
later, heterotopic ardiac transplantation was done with a heart from an 
RP rat. Control rats had no pretreatment or received antilympocyte serum 
alone. Without pretreatment, RP hearts survived 7 to 9 days (mean 8 days) 
in Lewis recipients (n = 5) and 9 to 14 days (mean 12 days) in Wistar Furth 
recipients (n = 5). Antilymphocyte serum alone produced slight prolonga- 
tion of graft survival. Lewis rats pretreated with class I disparate RP 
splenocytes and antilympocyte serum had graft survivals of 8 to 27 days 
(mean 14 days), not significantly different from the results with antilym- 
pocyte serum alone. Class II disparate RP grafts placed in pretreated 
Wistar Furth rats had significant prolongation of graft survival, with four 
of five grafts surviving longer than 60 days (p < 0.01 vs antilympocyte 
serum alone). These results suggest hat a disparity at the class II locus of 
the major histocompatibility complex is critical for the induction of cardiac 
allograft tolerance after intrathymic inoculation of allogeneic cells. 
(J Thorac Cardiovasc Surg 1996;112:1315-8) 
I nduction of donor-specific unresponsiveness rep- resents an ideal strategy through which survival of 
tissue or organ allografts could be promoted without 
chronic host immunosuppression. I definite donor- 
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specific tolerance to a cardiac allograft disparate in 
both class I and class II major histocompatibility 
complex (MHC) antigens was achieved in our labo- 
ratory and others through the pretransplant intra- 
thymic injection of donor spleen cells and a single 
intraperitoneal injection of antilymphocyte serum 
(ALS). 1-4 The underlying mechanism of tolerance in 
this model has not yet been defined. It is commonly 
believed that a form of self-tolerance induced in the 
thymus is altered by the injection of cells expressing 
foreign antigens. Recently, several experiments have 
addressed the issue of whether donor MHC alloan- 
tigens are necessary for the intrathymic induction of 
tolerance. 5-7 In previous experiments, we showed 
that the efficacy in prolonging cardiac allograft 
survival of intrathymic pretreatment with allogeneic 
cells is related to the degree of donor-recipient 
histoincompatibility. 4 This study, which is an exten- 
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Table I. Survival of cardiac allografls in MHC mismatched recipients pretreated by intrathymic injection with 
donor allogeneic antigens 
Survival (days) 
Group Donor Recipient MHC mismatch Pretreatment Raw values Mean p* 
a RP Lewis Class I None 7, 7, 9, 9, 9 8.2 - -  
RP WF Class II None 9, 11, 13, 14, 14 12.2 - -  
b RP Lewis Class I IP ALS 9, 10, 13, 13, 14 11.8 <0.05t 
RP WF Class II IP ALS 13, 14, 14, 15, 15 14.2 NSt 
c RP Lewis Class I IT RPSC 8, 10, 11, 13, 27 13.8 NS:~ 
RP WF Class II IT RPSC 19, >60, >60, >60, >60 51.8 <0.015 
NS, not significant; RPSC, splenocytes from RP rat. 
*Unpaired two-tailed t test. 
tVersus group a. 
:Wersus groups a and b. 
sion of  our investigations on histocompatibility dif- 
ferences and cardiac transplant olerance produced 
by intrathymic pretreatment, was designed to deter- 
mine whether the donor-specific tolerance produced 
by intrathymic pretreatment was reproducible with 
grafts differing in either class I MHC only or class II 
MHC only. 
Materials and methods 
Animals. The rat MHC (RT1) is subdivided into five 
loci (A, B, C, D, and E). 8 The rat RTIA and RTIC 
regions encode class I (major) and class I (medial) 
transplantation antigens, respectively. The RT1B and 
RTID regions encode class II transplantation antigens. 
RP (RT1 AuB1D1), Lewis (RT1 A1B1D1C1), and Wistar 
Furth (WF; RT1 AuBuDuCu) rats were used in these 
experiments. The RP and Lewis strains have class I MHC 
histoincompatibilities, whereas the RP and WF strains are 
class II MHC histoincompatible. All rats studied were 
male adults (200 to 250 gm). RP rats were bred at the 
Central Animal Facilities of Erasmus University (Rijswijk, 
The Netherlands). The other strains were obtained from 
Harlan Sprague Dawley, Inc. (Indianapolis, Ind.). All 
animals were kept in a virus-free facility at the Medical 
College of Pennsylvania Hospital and were handled in a 
humane fashion in accord with Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Experimental design. Donors of cells and hearts in all 
experiments were RP rats. Grafts were done with the 
following strain combinations and across the following 
histoincompatibility lines: class I MHC, RP into Lewis; 
class II MHC, RP into WF. Recipient animals were 
divided into three subgroups: group a, no pretreatment; 
group b, intraperitoneal injection of ALS only; and group 
c, ALS and intrathymic pretreatment with splenocytes 
from RP donors. 
Preparation of donor spleen cells. Whole RP spleens 
were removed through a midline incision. Spleens were 
disrupted by use of a tissue homogenizer and suspended 
in RPMI 1640 medium (Sigma Chemical Co., St. Louis, 
Mo.). Red blood cells were lysed with ammonium chlo- 
ride. Remaining white blood cells were washed with 
RPMI 1640 medium. Viability of the cells was evaluated 
by trypan blue dye exclusion. 
Pretreatment of graft recipients. On the day before 
intrathymic treatment, recipient rats received 1 ml ALS 
intraperitoneally. The next day, after metofane inhalation 
anesthesia was induced, the thymus of the recipient rat 
was exposed by a partial median sternotomy and a dose of 
2.5 × 107 donor splenocytes in a volume of 0.05 ml was 
injected into both lobes of the thymus under direct vision. 
Heart transplantation. Three weeks after pretreatment 
or injection of ALS alone, recipient animals underwent 
transplantation under metofane anesthesia with hearts 
from donors of the same strains as those used to obtain 
splenocytes for intrathymic injection. Hearts were trans- 
planted heterotopically in the manner described by Ono 
and Lindsey. 9Graft viability was assessed by daily abdom- 
inal palpation; if palpation was indeterminate, viability 
was assessed by direct visualization. Rejection, marked by 
the complete absence of ventricular contractions, was 
confirmed histologically. 
Histopathology. The rejected hearts were examined 
with routine histopathologic staining. Sections of rejected 
hearts were fixed in 10% buffered formalin and embedded 
in paraffin. Staining was carried out with hematoxylin and 
eosin. Slides were examined by light microscopy. 
Statistical analysis. Comparison between groups was 
done with an unpaired two-tailed Student's t test. 
Results 
Heart graft survivals are summarized in Table I. 
Heart grafts transplanted across either class I MHC 
or class II MHC mismatch strain combinations were 
all rejected by untreated recipients; they survived 7 
to 9 days (mean 8 days) and 9 to 14 days (mean 12 
days), respectively. After administration of ALS 
only cardiac graft survival was slightly prolonged 
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(mean 12 days, p < 0.05 vs unpretreated group) for 
Lewis recipients (class I MHC disparate strain com- 
bination) but was not prolonged (mean 14 days, p 
not significant) for WF recipients (class II MHC 
disparate strain combination). 
The results for the two class MHC disparate strain 
combinations were quite different after intrathymic 
pretreatment. Graft survival for Lewis rats pre- 
treated with class I disparate RP splenocytes and 
ALS ranged from 8 to 27 days (mean 14 days), not 
significantly different from the effect of ALS alone. 
Class II mismatched RP grafts placed in WF rats 
after intrathymic pretreatment had significant pro- 
longation of graft survival, with four of five grafts 
surviving longer than 60 days (p < 0.01 vs ALS 
alone). 
Discussion 
Previous experiments confirmed the role of the 
thymus in the induction and maintenance of specific 
immunologic unresponsiveness to organ allo- 
grafts.2, 5. 10 One theory hypothesizes that introduc- 
tion of allogeneic ells into the thymus alters the 
immunologic milieu in which new T cells mature. 
When immature lymphoid cells from the bone mar- 
row circulate through the thymus, their develop- 
ment takes place in the presence of alloantigens 
presented as "self." In normal immune ontogeny, 
self-reactive cells are eliminated in the thymus. This 
process leads to the development of a repertoire of 
T cells that do not recognize the allogeneic ells in 
the thymus as foreign. Previous work suggests that 
the thymic environment can be manipulated to 
result in the development of donor-specific toler- 
ance across an MHC barrier but not across a 
non-MHC barrier. 4' 11 Goss, Nakafusa, and Flye 6 
showed that the form of donor MHC alloantigens 
placed in the thymus is critical for the induction of 
donor-specific tolerance and allograft acceptance. 
This study provides further evidence that specific 
requirements for antigen presentation i the thymus 
are quite stringent, even in this rodent model. 
Proper presentation of foreign antigens in the 
thymus is required for tolerance induction by intra- 
thymic pretreatment. This study was designed to test 
whether class I MHC only or class II MHC only 
disparate cells were effective in producing cardiac 
allograft tolerance after intrathymic inoculation. 
Our results showed that graft tolerance was ob- 
served in the class II MHC mismatched strains but 
not in class ! MHC mismatched strains. Class I 
disparate antigens thus do not appear to be effec- 
tively presented in the thymic milieu for the induc- 
tion of graft tolerance. The reason for this is not 
clear. It may relate to antigen processing in the 
thymus or elsewhere, or to the fact that class II 
antigens, unlike class I MHC antigens, are not 
expressed constitutively on all somatic cells, espe- 
cially endothelial cells. 
Additionally, our previous studies showed that 
prolongation of graft survival was longest in strain 
combinations that differed at the full MHC locus 
(both class I and class II) after pretreatment with 
ALS and intrathymic donor alloantigens. These 
findings suggest hat a necessary condition for the 
induction of tolerance to an experimental cardiac 
allograft by intrathymic pretreatment is the inocula- 
tion of class II MHC disparate antigens. 
As in a previous study, 4 slight prolongation of 
graft survival was observed in recipients injected 
with ALS alone. One dose of ALS produces 
transient reduction in all classes of circulating 
lymphocytes. The time course of this reduction is 
such that the recipient animal has not completely 
regained normal circulating levels of immune 
competent cells by 3 weeks, the time of engraft- 
ment. Presumably, this nonspecific immunosup- 
pressive ffect leads to slight prolongation of graft 
survival in this model. 
In summary, our study demonstrates that a dis- 
parity at the class II locus of the MHC is critical for 
the induction of cardiac allograft tolerance after 
intrathymic inoculation of allogeneic ells. Applica- 
tion of these principles could have implications for 
clinical transplantation. 
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